Imagine if you could take a medicine already approved for one illness and find out it actually fixes a completely different disease. Instead of guessing, this project uses AI to look at the body's molecular 'wiring' to match the right old drug to the right patient. It's like finding a new use for a tool you already own, saving years of trial and error.
Developing new drugs is too slow and expensive, and most treatments only address symptoms because the molecular causes of diseases are poorly understood.
An integrated AI and network-pharmacology toolbox and an open-access web platform for bioinformatics analysis and drug-disease matching.
If you are a drug discovery firm dealing with the high cost and slow speed of creating new compounds — this project developed an AI and network-pharmacology toolbox that identifies existing drugs for new uses. This cuts years of development time and reduces costs.
If you are a biotech SME dealing with stalled innovation for rare diseases — this project developed a platform to identify causal molecular mechanisms. This allows you to create precise, low-dose drug combinations with fewer side effects.
If you are a software provider dealing with fragmented multi-omics data — this project developed an open-access platform for bioinformatics analysis. It enables the stratification of patients by endotype rather than just symptoms.
Based on available project data, it repurposes existing, approved drugs instead of discovering new compounds, which cuts years of development time and cost.
The project has developed an AI toolbox currently in alpha testing and is establishing a pan-European network for precision trials, indicating a transition toward a sustainable European infrastructure.
REPO4EU provides specific expertise and matchmaking for freedom-to-operate, intellectual property, and value-creation for drug repurposing projects.
The project runs from 2022 to 2029, with a plan to convert the platform into a sustainable European infrastructure after a 2-year interphase.
The project is aligned with the European Health Data Space and the EU Pharmaceutical Strategy to ensure regulatory alignment.
The consortium is heavily weighted toward commercial application, with a 59% industry ratio comprising 17 industry partners, 15 of which are SMEs. This strong industrial presence, combined with 9 universities across 10 countries, suggests a high focus on translating AI bioinformatics into marketable therapeutic assets.
Contact Universiteit Maastricht regarding the REPOSYSTEM infrastructure
Contact us to match your drug pipeline with the REPO4EU AI toolbox.
